Close Menu

NEW YORK – Myriad Genetics submitted a supplemental premarket approval application with the US Food and Drug Administration for myChoice CDx to assess newly diagnosed advanced ovarian cancer patients with homologous recombination deficiency (HRD), who are likely to respond to niraparib (GlaxoSmithKline's Zejula).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.